Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPCLUSA vs ZEPATIER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EPCLUSA is a fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor. Sofosbuvir inhibits HCV RNA replication by acting as a chain terminator, while velpatasvir inhibits HCV replication by binding to NS5A and disrupting viral RNA replication and assembly.
ZEPATIER is a fixed-dose combination of elbasvir, an HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. Elbasvir inhibits HCV NS5A, disrupting viral replication and assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein into mature viral proteins.
Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years and older,Treatment of genotype 1, 2, 3, 4, 5, or 6 HCV infection without cirrhosis or with compensated cirrhosis,Treatment of genotype 1, 2, 3, 4, 5, or 6 HCV infection with decompensated cirrhosis (in combination with ribavirin)
Treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults,Treatment of chronic HCV genotype 1 or 4 infection in pediatric patients 12 years of age and older or weighing at least 30 kg
400 mg sofosbuvir / 100 mg velpatasvir orally once daily with or without food for 12 weeks.
One tablet (elbasvir 50 mg/grazoprevir 100 mg) orally once daily.
Sofosbuvir: 0.4 hr (parent), 27 hr (GS-331007); Velpatasvir: 15 hr. Clinical context: once-daily dosing achieves steady-state in ~1 week.
Elbasvir: terminal half-life approximately 24 hours. Grazoprevir: terminal half-life approximately 31 hours. The prolonged half-lives support once-daily dosing and allow for sustained viral suppression.
Sofosbuvir is metabolized in the liver to its active metabolite (GS-461203) via cathepsin A (Cat A) and CES1, followed by phosphorylation. Velpatasvir is metabolized primarily by CYP2B6, CYP2C8, and CYP3A4.
Elbasvir is metabolized primarily by CYP3A. Grazoprevir is metabolized primarily by CYP3A. Mild oxidation and glucuronidation are minor pathways.
Sofosbuvir: 80% renal (as inactive metabolite GS-331007), 14% fecal; Velpatasvir: 94% fecal, 0.4% renal.
Elbasvir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Grazoprevir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Renal elimination is negligible for both.
Sofosbuvir: 61-65% (human plasma proteins); Velpatasvir: >99.5% (mainly albumin, alpha-1 acid glycoprotein).
Elbasvir: ≥99.9% bound, primarily to albumin and α1-acid glycoprotein. Grazoprevir: 98.8% bound, primarily to albumin and α1-acid glycoprotein.
Sofosbuvir: ~69 L (calculated as Vd/F); Velpatasvir: ~130 L (calculated as Vd/F). Not typically expressed per kg; indicates extensive tissue distribution.
Elbasvir: apparent Vd approximately 4.5 L/kg (high, indicating extensive tissue distribution). Grazoprevir: apparent Vd approximately 19 L/kg (very high, likely due to binding to plasma proteins and tissue uptake).
Sofosbuvir: ~92% (oral, with food); Velpatasvir: ~25% (fasted), increased with high-fat meal (up to 2-fold).
Elbasvir: absolute bioavailability not determined in humans; oral absorption is high. Grazoprevir: absolute bioavailability approximately 27% after oral administration; absorption is enhanced with food (high-fat meal increases AUC by 1.5-fold).
No dose adjustment required for GFR ≥30 m L/min. Safety and efficacy not established for GFR <30 m L/min or hemodialysis; use with caution and consider alternative therapy.
No dose adjustment required for any degree of renal impairment including end-stage renal disease on dialysis.
No dose adjustment for mild or moderate hepatic impairment (Child-Pugh A or B). Not recommended for use in severe hepatic impairment (Child-Pugh C) due to higher exposures of velpatasvir.
Contraindicated in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment required in mild (Child-Pugh A) hepatic impairment.
For patients ≥6 years old or weighing ≥17 kg: fixed-dose combination (400 mg/100 mg) once daily with or without food, regardless of weight, for 12 weeks. Safety and efficacy not established for children <6 years or weighing <17 kg.
Not approved for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment required based on age; use same dosing as younger adults, with monitoring for comorbidities and potential drug interactions.
No dose adjustment required; however, clinical studies indicate similar safety and efficacy as in younger adults, but caution is warranted due to potential age-related comorbidities.
Risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV. Test all patients for evidence of current or prior HBV infection before initiating treatment. Monitor for HBV reactivation during and after treatment.
Risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV, which may result in fulminant hepatitis, hepatic failure, and death. Test all patients for evidence of current or prior HBV infection before initiating treatment.
Risk of HBV reactivation in patients coinfected with HCV and HBV,Increased risk of bradycardia when used with amiodarone, especially in patients on beta-blockers or with cardiac comorbidities,Possible decreased therapeutic effect with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort),Not recommended in patients with severe renal impairment (e GFR <30 m L/min) or end-stage renal disease requiring dialysis
Risk of hepatitis B virus reactivation,Hepatic decompensation with use in patients with moderate or severe hepatic impairment (Child-Pugh B or C),Elevation of total bilirubin and/or ALT levels,Risk of adverse reactions due to drug interactions (e.g., strong CYP3A inducers/inhibitors)
Concomitant use with amiodarone (risk of symptomatic bradycardia),Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort)
Moderate or severe hepatic impairment (Child-Pugh B or C),Use with strong CYP3A inducers (e.g., rifampin, St. John's wort, carbamazepine, phenytoin),Use with certain HIV medications (e.g., efavirenz, etravirine, nevirapine, atazanavir/ritonavir, lopinavir/ritonavir, darunavir/ritonavir, tipranavir/ritonavir),Use with cyclosporine
Take with or without food. No specific dietary restrictions. Avoid grapefruit juice? No interaction reported. Avoid alcohol as it can worsen liver disease.
ZEPATIER can be taken with or without food. No specific food restrictions are required. Grapefruit and grapefruit juice may increase exposure to grazoprevir; although not contraindicated, consider avoiding large quantities.
EPCLUSA (sofosbuvir/velpatasvir) is contraindicated in pregnancy due to the teratogenic risk associated with ribavirin (if used in combination). In the absence of ribavirin, there are no adequate human data; animal studies show no evidence of teratogenicity at clinically relevant exposures. However, due to the potential for ribavirin co-administration in some HCV regimens, pregnancy must be excluded before initiation and avoided during treatment and for 6 months after in females of childbearing potential.
ZEPATIER (grazoprevir/elbasvir) is contraindicated in pregnancy due to the ribavirin component in some regimens. Ribavirin is teratogenic in all trimesters, causing fetal malformations and embryolethality. Grazoprevir/elbasvir alone has no adequate human data, but animal studies show no teratogenicity. However, combination with ribavirin mandates avoidance in pregnancy.
No data on the presence of sofosbuvir or velpatasvir in human milk, effects on the breastfed infant, or milk production. Because of the potential for adverse effects in the breastfed infant, breastfeeding is not recommended during treatment and for 6 months after the last dose, especially if ribavirin is co-administered. M/P ratio: unknown.
No data on human milk excretion. M/P ratio unknown. Ribavirin accumulates in breast milk and is contraindicated during breastfeeding. Grazoprevir/elbasvir: animal studies show excretion in milk; potential for adverse effects. Avoid breastfeeding during treatment and for 7 days after last dose.
No dose adjustment is recommended for EPCLUSA based on pregnancy alone. However, pharmacokinetic changes in pregnancy may alter drug exposure; therapeutic drug monitoring is not currently recommended. Safety and efficacy in pregnant women have not been established.
No dose adjustment studies in pregnancy. ZEPATIER is not recommended during pregnancy due to ribavirin component. If inadvertently used, no specific dose adjustment; consult maternal-fetal specialist.
EPCLUSA (sofosbuvir/velpatasvir) is a pangenotypic NS5B polymerase inhibitor and NS5A inhibitor combination for chronic HCV. For decompensated cirrhosis (Child-Pugh B/C), co-administer with ribavirin. Monitor for bradycardia when used with amiodarone; avoid co-administration if possible. Check for polymorphisms at baseline if HCV genotype 3 and cirrhosis (consider extending treatment). Assess renal function; not recommended if e GFR <30 m L/min/1.73m² unless on dialysis and benefit outweighs risk.
ZEPATIER (elbasvir/grazoprevir) is indicated for chronic HCV genotypes 1 or 4. Prior to initiation, test for NS5A resistance-associated substitutions (RASs) in genotype 1a. In patients with genotype 1a and baseline NS5A RASs, treatment duration is 16 weeks with ribavirin. Avoid in moderate to severe hepatic impairment (Child-Pugh B or C). Monitor hepatic function closely. Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) is contraindicated. Also contraindicated with OATP1B1/3 inhibitors (e.g., cyclosporine) and certain HIV protease inhibitors (e.g., atazanavir, darunavir, lopinavir). Grazoprevir increases serum creatinine due to OATP2B1 inhibition, but this does not reflect true renal function decline.
Take one tablet (400 mg sofosbuvir/100 mg velpatasvir) orally once daily with or without food.,Complete the full course of treatment (12 weeks for most patients; 24 weeks for genotype 3 with cirrhosis or prior treatment failure).,Use of amiodarone with EPCLUSA can cause serious slowing of heartbeat (bradycardia). Inform your doctor if you take amiodarone.,Avoid taking rifampin, St. John's wort, or certain anticonvulsants (carbamazepine, phenytoin) as they reduce EPCLUSA effectiveness.,Report any symptoms of hepatitis B reactivation (fatigue, jaundice, dark urine) immediately.,If you have diabetes, monitor blood glucose closely as treatment may improve glucose control.,Use effective contraception during treatment and for 6 months after if using combined oral contraceptives containing ethinyl estradiol.
Take ZEPATIER exactly as prescribed, one tablet once daily with or without food.,Do not stop or skip doses without consulting your healthcare provider.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements, to avoid serious interactions.,Notify your healthcare provider immediately if you experience symptoms of liver problems: yellowing of skin or eyes, dark urine, pale stools, nausea, vomiting, or right upper abdominal pain.,ZEPATIER may elevate creatinine levels without reflecting kidney damage; your doctor will monitor appropriately.,If you have genotype 1a HCV, your doctor will test for specific resistance mutations to determine the correct treatment duration.,Avoid alcohol during treatment as it can exacerbate liver injury.,Use effective contraception during treatment and for 2 weeks after the last dose if you or your partner can become pregnant.
No interactions on record
No interactions on record
Common clinical questions about EPCLUSA vs ZEPATIER, answered by our medical review team.
EPCLUSA is a Direct-Acting Antiviral (DAA) for Hepatitis C that works by EPCLUSA is a fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor. Sofosbuvir inhibits HCV RNA replication by acting as a chain terminator, while velpatasvir inhibits HCV replication by binding to NS5A and disrupting viral RNA replication and assembly.. ZEPATIER is a Direct-Acting Antiviral (HCV) that works by ZEPATIER is a fixed-dose combination of elbasvir, an HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. Elbasvir inhibits HCV NS5A, disrupting viral replication and assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein into mature viral proteins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPCLUSA and ZEPATIER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPCLUSA is: 400 mg sofosbuvir / 100 mg velpatasvir orally once daily with or without food for 12 weeks.. The standard adult dose of ZEPATIER is: One tablet (elbasvir 50 mg/grazoprevir 100 mg) orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPCLUSA and ZEPATIER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPCLUSA is classified as Category C. EPCLUSA (sofosbuvir/velpatasvir) is contraindicated in pregnancy due to the teratogenic risk associated with ribavirin (if used in combination). In the absence of ribavirin, there . ZEPATIER is classified as Category C. ZEPATIER (grazoprevir/elbasvir) is contraindicated in pregnancy due to the ribavirin component in some regimens. Ribavirin is teratogenic in all trimesters, causing fetal malformat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.